Innovation Fund of the Republic of Serbia Project
Novelic, has a 70% co-financed project by the Innovation Fund of the Republic of Serbia, being financed by
EU and the Republic of Serbia sources:
HUDES, HUman DEtection Sensor
In the project, Novelic is co-financing activities within Faculty of the Electrical Engineering of University
H2020 Program Project
Novelic is actively supporting partnerships in the EU Research Programs as SME and continuously looking for
H2020 interdisciplinary and focused partnership on:
- Contactless sensors
- Wireless and wired communication
- Signal processing solutions and implementations on target platforms or ASICs
- Embedded HW/SW platforms, system demonstrators and field trails
Novelic is listed on the Cordis database.
We have R&D activities on:
- 60 GHz Radar Sensor IPs (mm-Wave IC, antenna systems and signal processing)
- Technologies for Gigabit Wireless Data Transfers (Cryptography)
- Wirelessly controlled mobile platforms with data exchange
- Data acquisition and control systems
- New generation of bio-sensors enabled systems for medical use
In the scope of the European Horizon 2020 Program and being part of the GLAM Project Consortia
GLAM – novel photonic based point-of-care device for cancer diagnosis.
Novelic is participating in multidisciplinary R&D activities, targeting new sensor system development for health care and medical use.
The major task of Novelic in the GLAM Project is to contribute to system design and design of integrated portable device, based on novel photonic sensors.
As an innovative SME, Novelic is also taking the role of the Exploitation manager in the project, providing the first interface for GLAM Technology transfer in the future product.
GLAM’s is introducing the disruptive technology for medicine and health care markets. GLAM will design and develop a new diagnostic tool to detect biomarkers from biofluids obtained in a non-invasive manner, focusing to urine and to genitourinary cancers, to help oncologist to take better treatment decisions, approaching personalized medicine. GLAM capitalizes on the unprecedented sensitivity achieved using laser microring resonators to detect key biomarkers in tumor development and treatment. Point of Care of the device will be carried out by preclinical and clinical sample analysis of genitourinary cancer patients to warrant personalized medicine. Importantly the GLAM unique technology will make the device also usable with other biofluids and might also be used to help physicians with another biomarker driven. The project will develop an integrated device based on novel label-free photonic biosensors with ultra-sensitivity, simplicity of use, portability, multiplexing and low cost. For more information on the field, please contact us.
GLAM is coordinated by Leitat Technological Center in Spain. The 4-years Project joined recognized organisations: IBEC (ES), University of Twente (NL), WizSoft LTD (IL), Université libre de Bruxelles (BE), ICFO (ES), Radboud University Medical Center (NL), NOVELIC DOO (SB), OPTOCAP LTD (UK) and OBELIS SA (BE).